Clinical trials: Mild Asthma
Asthma
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)
This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks.
- Trial name
- NCT00442351
- Testing
- Asmanex twisthaler
- Volunteers
- 26 people
- Sponsor
- Organon and Co
Asthma
A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise
This study is intended to determine the dose response and duration of action of GSK2190915 in mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.
- Trial name
- NCT00812929
- Testing
- GSK2190915
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total.
- Trial name
- NCT00999466
- Testing
- AZD8848
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Asthma
A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma
This study aims to provide data in adult participants with mild to moderate asthma to assist healthcare professionals (HCPs) in assessing various attributes of ELLIPTA and BREEZHALER DPIs, by comparing the incidence of critical…
- Trial name
- NCT04813354
- Testing
- ELLIPTA, BREEZHALER
- Where
- 3 sites in Netherlands
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Asthma
BI 443651 Methacholine Challenge
The primary objective of this study is to investigate safety and tolerability of three consecutive administrations, 12 hours apart, at three different dose-levels of BI 443651 administered via oral inhalation in male and female…
- Trial name
- NCT03135899
- Testing
- BI 443651
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Asthma
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of…
- Trial name
- NCT02322775
- Testing
- Benralizumab
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Asthma
Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from…
- Trial name
- NCT01128595
- Testing
- FF/GW642444M, GW642444M, Fluticasone Furoate
- Where
- 4 sites in Australia, New Zealand and 1 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Asthma
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001)…
- Trial name
- NCT02433834
- Testing
- Glycopyrronium MDI, Serevent Diskus 50 μg
- Where
- 43 sites in United States
- Volunteers
- 248 people
- Sponsor
- Pearl Therapeutics, Inc.
Healthy Volunteers, Asthma
Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals
RP3128 is a calcium release activated calcium (CRAC) channel modulator. The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending dose(s) of RP3128 in healthy…
- Trial name
- NCT02958982
- Testing
- RP3128
- Where
- Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Rhizen Pharmaceuticals SA
Asthma
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
This study will be an open-label, parallel-group comparison of Mometasone Furoate Dry Powder Inhaler (MF-DPI) 200 mcg once daily in the evening with two puffs vs.
- Trial name
- NCT00442117
- Testing
- mometasone furoate dry powder inhaler, Budesonide DPI
- Volunteers
- 180 people
- Sponsor
- Organon and Co
Cat Allergy, Mild Asthma
Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
The primary objective is to evaluate the prophylactic efficacy of REGN1908-1909 (anti-Fel d 1) administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat in the prevention of a Controlled Cat…
- Trial name
- NCT03838731
- Testing
- REGN1908-1909
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Regeneron Pharmaceuticals
Wheezing, Reactive Airway Disease
A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma
The primary objective of this study is to evaluate budesonide levels in the blood following inhalation of single doses of VR647 Inhalation Suspension in children with wheezing, reactive airway disease or mild asthma using a…
- Conditions
- Wheezing, Reactive Airway Disease, Mild Asthma
- Trial name
- NCT03421730
- Testing
- VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Vectura Limited
Asthma
First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma
GSK3511294 is a humanized monoclonal antibody antagonist of Interleukin (IL)-5 which is known to block binding of IL-5 to the IL-5 receptor complex, causing a reduction in the circulating population of eosinophils.
- Trial name
- NCT03287310
- Testing
- GSK3511294, Salbutamol/albuterol
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Asthma
Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic…
- Trial name
- NCT00995904
- Testing
- 84ug MAP0020, 42ug MAP0020, 21ug MAP0020
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Allergan
Asthma
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose treatment with MK-1029 in adults with mild to moderate persistent asthma.
- Trial name
- NCT01370317
- Testing
- MK-1029
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
To evaluate the PK profile of a single-dose of 140 mg subcutaneous (SC) administration of MEDI9929 (AMG 157) in adolescent subjects with mild to moderate asthma.
- Trial name
- NCT02512900
- Testing
- MEDI9929, 140 mg
- Where
- 4 sites in Poland
- Volunteers
- 21 people
- Sponsor
- MedImmune LLC
Asthma
Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in…
- Trial name
- ARIA (NCT02821416)
- Testing
- Benralizumab
- Where
- 6 sites in Canada
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Proctitis, Proctosigmoiditis
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who…
- Trial name
- NCT01008423
- Testing
- Budesonide
- Where
- 62 sites in United States
- Volunteers
- 281 people
- Sponsor
- Bausch Health Americas, Inc.
Asthma
Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)
The aim of this study is to compare the efficacy of ciclesonide with respect to reduction of the number of asthma exacerbations in children with mild persistent asthma.
- Trial name
- POPCICLE (NCT00163293)
- Testing
- Ciclesonide
- Where
- 7 sites in Canada, Hungary and 1 more
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
To Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva Respiratory…
- Trial name
- NCT03528577
- Testing
- Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Sun Pharmaceutical Industries Limited